Valeant Pharmaceuticals International has announced the acquisition of Aton Pharma, a specialty pharmaceutical company focused on ophthalmology and certain orphan drug indications, located in Lawrenceville, New Jersey.

Valeant raised $37m in funding from venture capitalists, including Aisling Capital, HealthCare Ventures and Johnson & Johnson Development Corp, for the buy.

The purchase of Aton follows a number of recent acquisitions by Valeant, including Brazil’s Instituto Terapeutico Delta in March, and an unnamed Brazilian company and Canada’s Vital Science Corp in April.